- Virtual
Democrats’ Last Chance for Drug Pricing Reform?
Where
Virtual
When
{{getUserDateTimeZone("1658336400").singleDate}}
{{getUserDateTimeZone("1658336400").time}} - {{getUserDateTimeZone("1658340000").time}} {{getClientTimeZoneName()}}
About
Once again Congress is barreling towards drug pricing reform, STAT will sit down with key decision makers to talk about the latest developments from Capitol Hill and the White House.
Featured Speakers:
Introduction:
- Brent Dover, CEO, Kalderos (sponsor speaker)
Part 1: A Top Senator’s View
- Sen. Ron Wyden (D-Ore.), Chairman of the Senate Finance Committee
- Rachel Cohrs, Washington correspondent, STAT (moderator)
Part 2: Listening to the Experts
- Rena Conti, Ph.D., associate professor, Department of Markets, Public Policy and Law, Questrom School of Business, Boston University
- Stacie B. Dusetzina, Ph.D., associate professor of health policy, Ingram associate professor of cancer research, Vanderbilt University School of Medicine
- Richard G. Frank, Ph.D., director of the USC-Brookings Schaeffer Initiative on Health Policy; fellow in economic studies; Margaret T. Morris professor of health economics, emeritus, department of health care policy, Harvard Medical School
- Rachel Cohrs, Washington correspondent, STAT (moderator)
More events in "Government/Policy"
The annual ASCO meeting is one of the leading showcases for new science about cancer treatment. STAT will take a deep look at the latest dat…
Pharmacy benefit managers are intermediaries that are supposed to negotiate lower drug costs. But does the system work for patients? And h…
